The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis.
The team’s research proposal was titled “A tight squeeze: engineering anti-fibrotic depot aerosols that circumvent the epithelia,” and the goal is to develop an inhaled medication that will reach fibrotic cells under the surface of the lung. According to RespiTech, the company will partner with Pharmaxis for the project, which will get underway later this year.
Read the RespiTech announcement.
